EUCTR2011-003777-28-GB进行中（未招募）1 期
Obeticholic acid treatment in patients with bile acid diarrhoea: an open-label, pilot study of mechanisms, safety and symptom response. - Obeticholic acid in bile acid diarrhoea
Imperial College London and Imperial College Healthcare NHS Trust0 个研究点目标入组 35 人开始时间: 2012年3月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients aged 18 - 80 who present at routine Gastrointestinal Outpatient Clinics at Hammersmith and Charing Cross Hospitals with chronic diarrhoea, defined as an average stool frequency of at least three per day, of Bristol Stool Type 6 or 7, for at least 3 months. Previous routine SeHCAT testing to establish the presence or absence of bile acid diarrhoea (BAD) unless there is evidence of TI disease/ resection. BAD will be defined as SeHCAT 7-day retention of less than 15% or diarrhoea in presence of TI disease/ resection. Study subjects will be grouped as having secondary BAD, due to ileal resection or Crohn's disease, or primary BAD, with no obvious cause. The third, control group having chronic diarrhoea but with normal SeHCAT retention (greater than 15%).
- •Female patients must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use = 1 effective (= 1% failure rate) method of contraception during the trial and for 15 days after the last dose of OCA. Male subjects with female partners of childbearing potential must use = 1 effective method of contraception. Effective methods of contraception are considered to be: 1. Established use of oral, injected or implanted hormonal methods of contraception. 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS). 3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. 4. Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). 5. True abstinence: When this is in line with the preferred and usual lifestyle of the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Patients with other diagnoses leading to diarrhoea, including colorectal neoplasia, ulcerative colitis, coeliac disease, chronic pancreatitis, drug-induced diarrhoea or active infection.
- •Patients who have not been investigated by standard clinical assessments to exclude these disorders.
- •Treatment with bile acid sequestrants (colestyramine, colestipol, colesevelam) for 2 weeks before the first dose of OCA. Loperamide use will be allowed up to 16mg/d in divided doses.
- •Previous biliary surgery, excluding cholecystectomy.
- •Abnormal bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase on more than 1 occasion.
- •Chronic liver disease
- •Chronic kidney disease
- •Active, serious medical disease with likely life expectancy less than 5 years
- •Active substance abuse including inhaled or injection drugs in the year prior to screening
- •Allergy to obeticholic acid.
- •Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use effective birth control during the trial, breast feeding. Pregnancy will be assessed with urinary ß-hCG pregnancy test.
- •Participation in an investigational new drug trial in the 30 days before randomisation
- •Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study
- •Failure to give informed consent
研究者
相似试验
已完成
2 期
Obeticholic Acid in Bile Acid DiarrhoeaPrimary Bile Acid MalabsorptionSecondary Bile Acid MalabsorptionChronic DiarrhoeaNCT01585025Imperial College Healthcare NHS Trust35
进行中（未招募）
不适用
Colesevelam, which is a medication which binds bile acid, to test in patients with Crohns diseaseMorbus CrohnMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2009-010727-91-DEMU München, Campus Großhadern
进行中（未招募）
1 期
Treatment of bile acid malabsorption with liraglutidEUCTR2018-003575-34-DKProfessor, Ph.d. MD. Filip Krag Knop50
进行中（未招募）
1 期
Treatment effect of colesevelam for bile acid diarrhoeaEUCTR2016-001452-22-DKZealand University Hospital170
已完成
不适用
Prospective study for treatment of common bile duct stones by biliary stent placementcommon bile duct stonesJPRN-UMIN000013434Department of Gastroenterology and Hepatology, Kyoto University80